Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no ...

Destiny 2 is pretty fun in the Renegades era, but there's one modifier that is only getting worse as time goes on, and it ...

New information emerges that suggests Embark Studios may be gearing up to release new ARC Raiders content much sooner than ...

Study supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in ...

ARC Raiders developer Embark says it is working on multiple new maps for its hit extraction shooter, as the studio finally ...

OctopusEffects, #Blender From the actual shot of the periwinkle, the Tutorial creates a complete periwinkle branch with both ...

That "Enemy Forces" bit is important, since it stops some sweatily-optimised, out-of-bounds-jumping, breakneck route from ...

Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...

The Embark Studios team may soon reveal ARC Raiders' development plans for 2026. For now, they have summarized the Cold Snap ...

Ocugen Inc (NASDAQ:OCGN) shares are up on Friday as the company is gaining traction following positive market sentiment.

Maze Therapeutics uses its Compass genetics platform to advance kidney and obesity drugs, with MZE829 Phase 2 data due in ...

Dungeons & Dragons' bloody handed new subclass is part Bhaalspawn, part Dark Urge, all teleporting terror - here's how to ...